Youjin Wang1, Jean Wactawski-Wende1, Lara E Sucheston-Campbell2,3, Leah Preus1, Kathleen M Hovey1, Jing Nie1, Rebecca D Jackson4, Samuel K Handelman5, Rami Nassir6, Carolyn J Crandall7, Heather M Ochs-Balcom1. 1. Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, The State University of New York, Buffalo, New York 14214. 2. College of Pharmacy, The Ohio State University, Columbus, Ohio 43210. 3. Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio 43210. 4. Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, The Ohio State University, Columbus, Ohio 43210. 5. Center for Pharmacogenomics, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210. 6. Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California 95616. 7. Division of General Internal Medicine and Health Sciences Research, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095.
Abstract
Context: Evidence supports a protective effect of menopausal hormone therapy (HT) on bone. However, whether genetic susceptibility modifies the association of HT and fracture risk is not sufficiently explored. Objective: The objective was to test an interaction between genetic susceptibility and HT on fracture risk. Design: We constructed two weighted genetic risk scores (GRSs) based on 16 fracture-associated variants (Fx-GRSs) and 50 bone mineral density variants (BMD-GRSs). We used Cox regression to estimate the main effects of GRSs and their interactions with HT on fracture risk. We estimated the relative excess risk due to interaction (RERI) as a measure of additive interaction. We also used the case-only approach to test for a multiplicative interaction. Setting: Forty US clinical centers. Participants: A total of 9922 genotyped white postmenopausal women (age, 50 to 79) from the Women's Health Initiative HT randomized trials. Main Outcome Measures: Adjudicated fracture incidence. Results: Both GRSs were associated with fracture risk per 1-unit increment in GRS (hazard ratio, 1.04 [95% confidence interval, 1.02 to 1.06] for Fx-GRS and hazard ratio, 1.03 [95% confidence interval,1.02-1.04] for BMD-GRS). We found no evidence for multiplicative interaction for either of the GRS. However, we observed a substantial additive interaction, where the highest quartile of both GRSs and randomization to placebo have excess fracture risk: Fx-GRS P for RERI = 0.047, BMD-GRS P for RERI = 0.046. Conclusions: These results suggest that HT reduces fracture risk in postmenopausal women, especially in those at highest genetic risk of fracture and low BMD.
Context: Evidence supports a protective effect of menopausal hormone therapy (HT) on bone. However, whether genetic susceptibility modifies the association of HT and fracture risk is not sufficiently explored. Objective: The objective was to test an interaction between genetic susceptibility and HT on fracture risk. Design: We constructed two weighted genetic risk scores (GRSs) based on 16 fracture-associated variants (Fx-GRSs) and 50 bone mineral density variants (BMD-GRSs). We used Cox regression to estimate the main effects of GRSs and their interactions with HT on fracture risk. We estimated the relative excess risk due to interaction (RERI) as a measure of additive interaction. We also used the case-only approach to test for a multiplicative interaction. Setting: Forty US clinical centers. Participants: A total of 9922 genotyped white postmenopausal women (age, 50 to 79) from the Women's Health Initiative HT randomized trials. Main Outcome Measures: Adjudicated fracture incidence. Results: Both GRSs were associated with fracture risk per 1-unit increment in GRS (hazard ratio, 1.04 [95% confidence interval, 1.02 to 1.06] for Fx-GRS and hazard ratio, 1.03 [95% confidence interval,1.02-1.04] for BMD-GRS). We found no evidence for multiplicative interaction for either of the GRS. However, we observed a substantial additive interaction, where the highest quartile of both GRSs and randomization to placebo have excess fracture risk: Fx-GRS P for RERI = 0.047, BMD-GRS P for RERI = 0.046. Conclusions: These results suggest that HT reduces fracture risk in postmenopausal women, especially in those at highest genetic risk of fracture and low BMD.
Authors: Cathy C Laurie; Kimberly F Doheny; Daniel B Mirel; Elizabeth W Pugh; Laura J Bierut; Tushar Bhangale; Frederick Boehm; Neil E Caporaso; Marilyn C Cornelis; Howard J Edenberg; Stacy B Gabriel; Emily L Harris; Frank B Hu; Kevin B Jacobs; Peter Kraft; Maria Teresa Landi; Thomas Lumley; Teri A Manolio; Caitlin McHugh; Ian Painter; Justin Paschall; John P Rice; Kenneth M Rice; Xiuwen Zheng; Bruce S Weir Journal: Genet Epidemiol Date: 2010-09 Impact factor: 2.135
Authors: Jane A Cauley; John Robbins; Zhao Chen; Steven R Cummings; Rebecca D Jackson; Andrea Z LaCroix; Meryl LeBoff; Cora E Lewis; Joan McGowan; Joan Neuner; Mary Pettinger; Marcia L Stefanick; Jean Wactawski-Wende; Nelson B Watts Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Marcia L Stefanick; Barbara B Cochrane; Judith Hsia; David H Barad; James H Liu; Susan R Johnson Journal: Ann Epidemiol Date: 2003-10 Impact factor: 3.797
Authors: Carolyn J Crandall; Vedat O Yildiz; Jean Wactawski-Wende; Karen C Johnson; Zhao Chen; Scott B Going; Nicole C Wright; Jane A Cauley Journal: BMJ Date: 2015-01-27